DEXAMETHASONE SODIUM PHOSPHATE injection, solution

国家: 美国

语言: 英文

来源: NLM (National Library of Medicine)

有效成分:

DEXAMETHASONE SODIUM PHOSPHATE (UNII: AI9376Y64P) (DEXAMETHASONE - UNII:7S5I7G3JQL)

可用日期:

Mylan Institutional LLC

INN（国际名称）:

DEXAMETHASONE SODIUM PHOSPHATE

组成:

DEXAMETHASONE PHOSPHATE 4 mg in 1 mL

给药途径:

INTRA-ARTICULAR

处方类型:

PRESCRIPTION DRUG

疗效迹象:

A. By intravenous or intramuscular injection when oral therapy is not feasible: 1. Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia. Nonsuppurative thyroiditis. Hypercalcemia associated with cancer. 2. Rheumatic Disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode o

產品總結:

Dexamethasone sodium phosphate injection, USP 4 mg/mL is for-intravenous, intramuscular, intra-articular, intralesional and soft tissue administration available as follows: NDC Number Fill volume Pack size 67457-419-01 1 mL Single-Dose Vial 25’s 67457-418-05 5 mL Multi-Dose Vial 25’s 67457-484-30 30 mL Multi-Dose Vial 25’s Dexamethasone sodium phosphate injection, USP 10 mg/mL is for intravenous and intramuscular injection only available as follows: NDC Number Fill volume Pack size 67457-483-10 10 mL Multi-Dose Vial 10’s Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] Protect from light. Sensitive to heat. Do not autoclave. Protect from freezing. Manufactured for: Mylan Institutional LLC Rockford, IL 61103 U.S.A. Manufacture by: Mylan Laboratories Limited Bangalore, India SEPTEMBER 2018 Novaplus is a registered trademark of Vizient, Inc.

授权状态:

Abbreviated New Drug Application

产品特点

DEXAMETHASONE SODIUM PHOSPHATE- DEXAMETHASONE SODIUM PHOSPHATE
INJECTION,
SOLUTION
MYLAN INSTITUTIONAL LLC
----------
DEXAMETHASONE SODIUM PHOSPHATE INJECTION, USP
RX ONLY
DESCRIPTION
Dexamethasone sodium phosphate, a synthetic adrenocortical steroid, is
a white or slightly yellow,
crystalline powder. It is freely soluble in water and is exceedingly
hygroscopic. The molecular weight
is 516.41. It is designated chemically as
9-fluoro-11β,17-dihydroxy-16α-methyl-21-
(phosphonooxy)pregna-1,4-diene-3,20-dione disodium salt. The empirical
formula is C
H FNa O P
and the structural formula is:
Dexamethasone sodium phosphate injection, USP is a sterile solution of
dexamethasone sodium
phosphate, and is supplied in 4 mg/ mL and 10 mg /mL.
Dexamethasone sodium phosphate injection, USP 4 mg/mL is a sterile
solution for intravenous,
intramuscular, intra-articular, intralesional and soft tissue
administration. Each mL contains:
ACTIVE: Dexamethasone sodium phosphate 4.4 mg (equivalent to
dexamethasone phosphate 4 mg).
PRESERVATIVES: Methylparaben 1.5 mg; Propylparaben 0.2 mg. INACTIVES:
Edetate Disodium 0.11 mg;
Sodium Citrate Anhydrous 10 mg; Citric Acid and/or Sodium Hydroxide
q.s to adjust pH 7.0 to 8.5 and
Water for Injection q.s to 1 mL.
Dexamethasone sodium phosphate injection, USP 10 mg/mL is a sterile
solution for intravenous or
intramuscular use only. Each mL contains:
ACTIVES: Dexamethasone sodium phosphate 11 mg (equivalent to
dexamethasone phosphate 10 mg).
PRESERVATIVES: Methylparaben 1.5 mg; Propylparaben 0.2 mg. INACTIVES:
Edetate Disodium 0.11 mg;
Sodium Citrate Anhydrous 10 mg; Citric Acid and/or Sodium Hydroxide
q.s to adjust pH 7.0 to 8.5 and
Water for Injection q.s to 1 mL.
22
28
2
8
CLINICAL PHARMACOLOGY
Dexamethasone sodium phosphate injection has a rapid onset but short
duration of action when
compared with less soluble preparations. Because of this, it is
suitable for the treatment of acute
disorders responsive to adrenocortical steroid therapy.
Naturally occurring glucocorticoids (hydrocortisone and